The Impact of Chatbot-aid on Promoting Self-management of Men's Health in the Post COVID-19 Era
Launched by CHENG-HSIN GENERAL HOSPITAL · Mar 9, 2023
Trial Information
Current as of July 25, 2025
Unknown status
Keywords
ClinConnect Summary
This clinical trial is studying the use of an AI chatbot to help men manage their health, specifically focusing on issues like enlarged prostate, lower urinary tract symptoms, and erectile dysfunction. The goal is to see if this digital tool can improve self-management and decision-making for men experiencing these health concerns, especially in the context of post COVID-19 care.
If you are a man between the ages of 45 and 80 and have symptoms related to prostate enlargement, you might be eligible to participate. You’ll need to have a mobile phone and be willing to download the chatbot app. Participants can expect to interact with the chatbot, which will provide helpful information and support for managing their health. It's important to note that individuals with psychosis are not eligible for this study. Overall, this trial aims to explore how technology can assist in better health management for men facing these common urological issues.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Age between 45 years to 80 years old
- • Prostate enlargement with lower urinary tract symptoms
- • Need a mobile phone and willing to download the line chatbot
- Exclusion Criteria:
- • Psychosis
About Cheng Hsin General Hospital
Cheng-Hsin General Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a robust framework for conducting research, the hospital fosters collaboration among multidisciplinary teams to explore new therapeutic options and enhance clinical practices. By leveraging state-of-the-art facilities and a patient-centered approach, Cheng-Hsin General Hospital aims to contribute significantly to the medical community and drive forward the development of effective treatments across various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Trial Officials
Kuang-Kuo Chen, MD, PhD
Principal Investigator
Cheng-Hsin General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials